

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2005/000099

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. Claim Nos. :

because they relate to subject matter not required to be searched by this Authority, namely :

Although claims 32-38, 41-42, and 45-46 encompass methods of treatment of a human or animal which this Authority is not obliged to search under Rule 39.1(iv) of the PCT, the search has been carried out based on the alleged effects of the compounds referred to therein.

2. Claim Nos. :

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :

3. Claim Nos. :

because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows :

see extra sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. : 1-39, 41-42 and 45-52

Remark on Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2005/000099

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7): C07K 19/00, A61K 38/26; A61K 38/22, A61P 3/10, C07K 14/605, C07K 14/595

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(7): C07K 19/00, A61K 38/26, A61K 38/22, A61P 3/10, C07K 14/605, C07K 14/595

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)
Delphion, Canadian Patent Database, CAPPlus, Pubmed; Keywords, glucagon-like peptide agonist, GLP agonist, exendin, gastrin, CCK, cholecystokinin, blood glucose, diabetes, insulin

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US5545618 B1 (BUCKLEY DL et al.) 13 August 1996	29, 32-37, 39, 41-42, 45-52
A	US6506724 B1 (AMYLIN PHARMACEUTICALS, INC., HILES RA et al.) 14 January 2003	29, 32-37, 39, 41-42, 45-52
P, X	WO2004037195 A2 (WARATAH PHARMACEUTICALS, INC., BRAND SJ. et al.) 6 May 2004 whole document	1-19, 32-39, 41-42 and 47-48

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :	
"A"	document defining the general state of the art which is not considered to be of particular relevance
"E"	earlier application or patent but published on or after the international filing date
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"	document referring to an oral disclosure, use, exhibition or other means
"P"	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 June 2005 (20-06-2005)	20 July 2005 (20-07-2005)
Name and mailing address of the ISA/CA Canadian Intellectual Property Office Place du Portage I, C114 - 1st Floor, Box PCT 50 Victoria Street Gatineau, Quebec K1A 0C9 Facsimile No.: 001(819)953-2476	Authorized officer Nicole Harris (819) 997-4541

10/587529

IAP11 Rec'd PCT/PTO 26 JUL 2006

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2005/000099

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO2004045640 A1 (WARATAH PHARMACEUTICALS, INC., CRUZ A) 3 June 2004	1-20, 25, 29, 32-39, 41-42, 47-48 and 51
P, Y	whole document	21-24, 26-28, 45-46, 49-50 and 52
P, A	WO2004096853 A1 (WARATAH PHARMACEUTICALS, INC., BRAND SJ. et al.) 11 November 2004	
P, A	WO2004105780 A2 (WARATAH PHARMACEUTICALS, INC., CRUZ A) 9 December 2004	

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No. PCT/CA2005/000099

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
US5545618	13-08-1996	WO9111457 A1 CA2073856 A1 DE69129226D D1 DE69129226T T2 EP0512042 A1 ES2113879T T3 JP3262329B2 B2 JP2001151798 A JP2003192698 A JP2004196825 A JP 2005132848A	08-08-1991 25-07-1991 14-05-1998 30-07-1998 11-11-1992 16-05-1998 04-03-2002 05-06-2001 09-07-2003 15-07-2004 26-05-2005
US6506724	14-01-2003	AU778002 B2 AU5284600 A AU2005200608 A1 CA2373266 A1 EP1181043 A2 JP2003501361T T US2004023871 A1 WO0073331 A2	11-11-2004 18-12-2000 10-03-2005 07-12-2000 27-02-2002 14-01-2003 05-02-2004 07-12-2000
WO2004037195	06-05-2004	AU2003243501 A1 AU2003283004 A1 AU2003285229 A1 CA2486584 A1 EP1511509 A1 US2004023885 A1 US2004209801 A1 US2004229810 A1 US2004266682 A1 WO03103701 A1 WO2004045640 A1	22-12-2003 13-05-2004 15-06-2004 18-12-2003 09-03-2005 05-02-2004 21-10-2004 18-11-2004 30-12-2004 18-12-2003 03-06-2004
WO2004045640	03-06-2004	AU2003243501 A1 AU2003283004 A1 AU2003285229 A1 CA2486584 A1 EP1511509 A1 US2004023885 A1 US2004209801 A1 US2004229810 A1 US2004266682 A1 WO03103701 A1 WO2004037195 A2	22-12-2003 13-05-2004 15-06-2004 18-12-2003 09-03-2005 05-02-2004 21-10-2004 18-11-2004 30-12-2004 18-12-2003 06-05-2004
WO2004096853	11-11-2004	None	
WO2004105780	09-12-2004	AU722004 B2 AU774746 B2 AU1331900 A AU2003231864 A1 AU2004218687 A1 CA2326741 A1 CA2494134 A1 EP1071447 A1 EP1509087 A2 IL138784D D0 JP2004506591T T SE0003508 A US5885956 A US6288301 B1 US6558952 B1 US2002081285 A1 US2004037818 A1 US2004209816 A1 WO0044400 A1 WO03100024 A2	20-07-2000 08-07-2004 18-08-2000 12-12-2003 04-11-2004 03-08-2000 04-12-2003 31-01-2001 02-03-2005 31-10-2001 04-03-2004 21-11-2000 23-03-1999 11-09-2001 06-05-2003 27-06-2002 26-02-2004 21-10-2004 03-08-2000 04-12-2003

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2005/000099

continuation of Box III

Group 1: Claims 1-31, 32(partially), 33-37, 38(partially), 39, 41-42(partially), 45-52(partially) are directed towards GLP-1 agonist and gastrin compositions and their use in regulating blood glucose levels.

Group 2: Claims 32 (partially), 38 (partially), 41(partially), and 45-52 (partially) are directed towards methods of treating or preventing disease using GLP-1 agonist and gastrin compositions.

Group 3: Claims 40, 41-42 (partially), 43-44 and 45-46(partially) and 49-52(partially) are directed towards contacting islet precursor cells with GLP-1 agonist and gastrin to induce islet neogenesis.

BEST AVAILABLE COPY